EMCURE PHARMACEUTICALS
Namita Thapar's Emcure Pharmaceuticals IPO opens on Wednesday. What GMP signals ahead of subscription
Emcure Pharmaceuticals' IPO opens for subscription on July 3rd with shares trading at a Rs 265 premium in the unlisted market. The IPO includes fresh equity shares worth Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore shares. Priced at Rs 960-1,008 per share, investors can bid for 14 shares per lot. The company targets to raise Rs 1,952 crore at the upper price range.
Shark tank fame Namita Thapar to rake in Rs 127 crore through Emcure Pharma IPO
Shark Tank's Namita Thapar, who is part of Emcure Pharmaceuticals' promoter group, is set to earn approximately Rs 127 crore through the upcoming IPO. Thapar, who acquired shares in Emcure at an average price of Rs 3.44 each, will sell around 12.68 lakh shares through the OFS component of the IPO. With the upper price band set at Rs 1,008 per share, the stake sale is expected to yield about Rs 127 crore.
Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issue
Emcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximately Rs 1,952 crore through the public offer. Market analysts indicate that the current GMP of the pharma company stands at Rs 260 in the unlisted market.
IPO Calendar: Primary market gears up for another robust week as 3 companies look to raise Rs 2,700 cr
Apart from the above 3 public offers, the Street will see as many 11 listings including that of Allied Blenders and Vraj Iron and Steel, which received healthy investors' response for their IPOs in the week gone by.
Emcure Pharma announces price band for Rs 1,952-crore IPO at Rs 960-1,008/share. Check GMP, other details
Emcure Pharmaceuticals has announced its initial public offering (IPO) with a price band of Rs 960 to Rs 1,008 per equity share. The subscription for the IPO will open on Wednesday, July 3, and close on Friday, July 5. The floor price and cap price of the issue are set at 96 times and 100.80 times the face value of the equity shares, respectively.
Bain Capital-backed Emcure Pharma to float IPO on July 3
Emcure Pharmaceuticals, backed by Bain Capital, is set to launch its IPO on July 3. The IPO includes fresh equity shares issuance and Offer of Sale. Proceeds will be used for debt payment and corporate purposes.
- Go To Page 1
Ola Electric, Emcure Pharma get Sebi nod for IPOs, setting stage for big listings
The Bengaluru-based company had filed its draft prospectus with Sebi in December last year. The issue comprises a fresh equity sale of Rs 5,500 crore and an offer-for-sale (OFS) of 95.2 million shares.
Emcure Pharmaceuticals receives SEBI nod for its IPO launch
Emcure Pharmaceuticals received SEBI nod for IPO launch after filing DRHP in December 2023. The IPO includes equity shares and an Offer of Sale by promoters. Proceeds will be used for debt payment. Emcure Pharmaceuticals is renowned for its global marketing of pharmaceutical products.
Expert panel to soon weigh plan to use generics for prescription drugs
An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (AIDAN). The IPA opposes the idea, arguing that it would lead to a surge of demand from trade channels, such as general pharmacy stores, which would not benefit patients.
Ola Electric, Emcure Pharma among 12 companies to launch IPOs in next 2 months
India's primary market anticipates over two dozen IPOs in the next two months, targeting to raise more than Rs 30,000 crore. 18 companies have received approval from SEBI to launch IPOs, aiming to raise over Rs 20,000 crore while an additional 37 companies have filed the DRHP to raise over Rs 50,000 crore and are awaiting approval, according to primedatabase.com. Here is a list of companies planning to launch their IPOs in the upcoming months:
IPO season is back with more than 2 dozen companies chasing Rs 30,000 crore
India's primary market anticipates a wave of IPOs with over two dozen companies planning to raise ₹30,000 crore. Investor confidence is high with the Modi government's return for a third term, ensuring stable governance and policies.
Emcure and its subsidiary Gennova settle legal dispute with HDT Bio over mRNA technology
Emcure Pharmaceuticals and its subsidiary Gennova have resolved all legal disputes with US-based HDT Bio Corp. The parties have entered into a long-term agreement to develop mRNA vaccines against various infectious diseases in India and other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT's patented mRNA vaccine technology in multiple fields
Pad up, there's a brand new deal street in town
Cricketers have signed at least half a dozen endorsement, investment, and collaboration deals during the Indian Premier League (IPL) over the past two-three weeks. MS Dhoni has been signed by nutrition startup Explosive Whey, French carmaker Citroen, and Emcure Pharmaceuticals. Virat Kohli has collaborated with Philips for a limited-edition, co-designed beard trimmer, while Yashasvi Jaiswal has been signed by wearables brand boAt.
Emergency healthcare startup Medulance raises $3 million
New Delhi-based startup Medulance has raised funds after running as a profitable bootstrapped company for six years. This round also saw participation from investors such as Dexter Capital, Boat founder Aman Gupta, and Emcure Pharmaceuticals’ executive director Namita Thapar.
Sanofi looks for accelerated growth in India; plans fast-tracking of product pipeline
Sanofi, a leading French pharmaceutical company, aims to expand its presence in the Indian market by introducing new drugs, enhancing localization efforts, and collaborating with domestic firms. Managing Director Rodolfo Hrosz highlights the significant growth potential in India and emphasizes the company's focus on addressing the diabetes segment.
Pharma raw material makers in race to tank up on CXO talent
Some of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded Sekhmet Pharmaventures, and Carlyle-backed Viyash Lifesciences and Sequent Scientific (animal API manufacturer).
‘Shark Tank India’ judge Namita Thapar silences trolls who claimed she succeeded with ‘daddy’s money’
The entrepreneur, who recently held an ‘Ask Me Anything’ session on Reddit, was initially taken aback when a Reddit user attacked her personally, stating that she would be nowhere without the support of her father Satish Mehta, the founder of Emcure Pharmaceuticals.
Emcure Pharma to launch IPO in 3 months: Namita Thapar of Shark Tank fame
Shark Tank fame and Executive Director of Emcure Pharmaceuticals, Namita Thapar said at the ET NOW Global Business Summit 2024 on February 10 that the company plans to go public within three months.
Bain Capital-backed Emcure Pharma files fresh IPO papers with Sebi
Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital.
Emcure Pharma gets relief in $950-million lawsuit
The US district judge James Robart upheld the Indian drug maker's argument that the court lacked jurisdiction over the company and dismissed the case without prejudice, which means it can be refiled.
Shaadi.com founder Anupam Mittal posts selfie, says he still works 70-hour a week
One user commended Mittal, stating, "You are an Entrepreneur, that's why. Tell me, if you are an employee in Infosys or any other company, where the only reason to work is money (even the salaries are like those offered by Infosys), then?" Anupam Mittal responded to the query, emphasising his unwavering dedication to hard work. He shared, "I was an employee once but treated my job the same as I do now."
71 IPOs worth more than Rs 1 lakh crore are waiting to hit Dalal Street
The largest IPO during this period, also the largest Indian IPO ever, was from LIC for Rs 20,557 crore. This was followed by Delhivery (Rs 5,235 crore) and Rainbow Children's (Rs 1,581 crore). Only 1 of the 14 IPOs (Delhivery) was from a new age technology company (NATC), pointing toward the slowdown in IPOs from this sector. The average deal size was a high Rs 2,533 crore.
Namita Thapar organises 'Top Gun: Maverick' screening for 200 Emcure employees, shares leadership lessons from the movie
The desi Shark held the special screen for her staff to drive away Monday blues.
Namita Thapar says yoga and meditation made her a 'better' person, increased productivity
The Emcure Pharma ED urged everyone to explore this 'calmer' way of life.
Gennova Biopharmaceuticals developing Omicron specific vaccine
Gennova Biopharmaceuticals, a subsidiary of Pune-based drugmaker Emcure Pharmaceuticals, is developing a Covid-19 vaccine on its mRNA platform which will target the Omicron variant, the strain that is driving the third coronavirus infection wave in the country.
Emcure Pharmaceuticals gets Sebi's go-ahead to float IPO
As part of the OFS, promoters — Satish Mehta will offload 20.30 lakh equity shares, Sunil Mehta will sell 2.5 lakh equity shares — and investor BC Investments IV Ltd will divest 99.5 lakh equity shares among others.
Emcure Pharma files DRHP for IPO
Pune-based Emcure Pharmaceuticals, one of India’s biggest unlisted pharma companies, filed its draft red herring prospectus (DRHP) with the market regulator Sebi on Thursday to raise money through an initial public offer.
Aim to take Emcure among top 5 pharma cos: MD
On being asked about the status of the vaccine, company's subsidiary Gennova is developing for COVID-19, Mehta said, "We are developing the vaccine and have completed the phase-1 trials.
Domestic pharma majors join hands for clinical trial of Molnupiravir for COVID-19 treatment
The clinical trial will be conducted for the treatment of mild COVID-19 in an outpatient setting and is expected to take place between June and September across India with the recruitment of 1,200 patients.
Load More
